Small Cap Stocks: 374Water, Canagold Resources, Ocean Power, Giyani Metals, NanoViricides, Viking Therapeutics, HIVE Digital Technologies, American Resources Corp, Ocean Power Technologies, 374Water Inc, Canagold Resources Ltd.

NanoViricides' Phase II clinical trials for NV-387 may reduce metastatic cancer risk after viral infections. Viking Therapeutics' Phase 2a weight loss trial showed strong efficacy but raised tolerability concerns. HIVE Digital Technologies entered a preferred partnership with Bell Canada to provide large-scale AI infrastructure. American Resources Corp signed a long-term supply agreement with Vulcan Elements for rare earth oxides. Ocean Power Technologies introduced an upgraded version of its Merrows Maritime Domain Awareness Solution. 374Water successfully removed toxic PFAS chemicals from landfill wastewater using its AirSCWO treatment system. Canagold Resources closed a C$4 million financing to advance its New Polaris gold project.

NanoViricides, Inc. (NYSE American:NNVC) is advancing its broad-spectrum antiviral drug NV-387 into Phase II clinical trials, aiming to reduce the risk of metastatic cancer resurgence following viral infections. The drug, which has shown promising results in reducing inflammation and protecting lungs, is being evaluated for its potential to prevent the awakening of "sleeping" cancer cells. NV-387 has already completed a successful Phase I clinical trial and is now moving forward to further test its efficacy and safety in a larger patient population.

The Phase II trials will focus on evaluating the drug's ability to reduce inflammation markers, particularly IL-6, which has been linked to an increased risk of cancer resurgence in viral infections such as COVID-19 and Influenza [1]. The company's President and Chairman, Anil R. Diwan, Ph.D., emphasized that NV-387 not only attacks the virus but also calms the human immune system, thereby minimizing the risk of cancer reawakening.

The ongoing global COVID-19 pandemic, with its endemic nature and frequent waves, underscores the need for effective antiviral treatments. NV-387, with its unique ability to protect against multiple viruses, including RSV, Influenza, and Measles, presents a significant advancement in the fight against viral infections. The drug's success in animal model studies, where it outperformed existing treatments like Tamiflu and Xofluza, highlights its potential clinical viability [2].

NanoViricides' focus on developing NV-387 for various viral infections, including RSV, COVID-19, and Influenza, aligns with the company's broader mission to create special purpose nanomaterials for antiviral therapy. The company's business model, based on licensing technology from TheraCour Pharma, Inc., positions it as a leader in the development of broad-spectrum antivirals.

As the company progresses with NV-387, investors and financial professionals should closely monitor the trial results and the potential market acceptance of this innovative treatment. The success of NV-387 could have a substantial impact on cancer patients in remission who are at risk of cancer recurrence due to viral infections.

References:
[1] https://news.cuanschutz.edu/cancer-center/covid-19-awaken-dormant-cancer-cells
[2] Centers for Disease Control and Prevention. COVID Data Tracker. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2025, August 18. https://covid.cdc.gov/covid-data-tracker